KALV - NASDAQ
KalVista Pharmaceuticals, Inc.
$26.95
+0.037%KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotKalVista Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
KalVista Pharmaceuticals, Inc. Cash Flow Statement
KALV • NASDAQ
| KalVista Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||
-164.3M | -183.4M | -126.6M | -92.9M | -82.3M | -46.2M | -29.1M | -20.8M | -15.8M | -18.6M | -11.4M | -7.2M | -5.7M | -2.1M | |
1.5M | 941K | 816K | 718K | 743K | 537K | 512K | 378K | 180K | 40K | 33K | 38K | 27K | 38K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -33K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 63K | -6K | |
0.0 | 12.3M | 21.9M | 9.9M | 0.0 | 7.1M | 4.4M | 3M | 1.1M | 394K | 118K | 36K | 238K | 47K | |
80.3M | 2.3M | -485K | -407K | 15.8M | 72K | 13K | -103K | -651K | -1.4M | -1.7M | 167.0 | 32K | 104K | |
954K | 15M | 15.2M | 7.4M | -12.3M | 8.3M | -20.6M | -18.8M | 25.8M | -4.2M | -210K | 784K | 460K | 35K | |
-81.6M | -152.9M | -89.2M | -75.3M | -78.1M | -30.2M | -44.8M | -36.4M | 10.6M | -23.7M | -13.2M | -6.4M | -4.9M | -1.8M | |
INVESTING ACTIVITIES | ||||||||||||||
-1.9M | -929K | -42K | -1.2M | -931K | -82K | -220K | -1.1M | -1.4M | -74K | -11K | -125K | -18K | -91K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -16.8M | (69.4M) | (0.0) | (34.1M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-84.8M | -30.6M | -189.2M | -98.2M | -136.9M | -201.2M | -49.8M | -79.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
105.4M | 122.5M | 105M | 140.9M | 195.7M | 53.6M | 66.8M | 11.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | -401K | 0.0 | 0.0 | 0.0 | 16.8M | -69.4M | -1.4M | 34.1M | -715K | 0.0 | 0.0 | 0.0 | |
(18.7M) | (91M) | -84.7M | (41.4M) | (57.9M) | -147.7M | (16.8M) | -69.4M | -1.4M | (34.1M) | -11K | -125K | -18K | -91K | |
FINANCING ACTIVITIES | ||||||||||||||
1.9M | 61.7M | 96.9M | 56.6M | 1.6M | 210.6M | 11.4M | 87.9M | 9.1M | 0.0 | 1K | 1K | 17K | 0.0 | |
160.7M | 98M | 0.0 | 0.0 | 0.0 | 0.0 | -54K | -209K | -151K | 0.0 | 0.0 | 0.0 | 388K | -389K | |
0.0 | 0.0 | 53.8M | 1.5M | 0.0 | 1.5M | 216K | 242K | 0.0 | 2K | 33M | 8.7M | 0.0 | 0.0 | |
162.6M | 159.7M | 150.7M | 58.1M | 1.6M | 212.1M | 11.6M | 87.9M | 9M | 2K | 33M | 8.7M | 6.4M | 5.6M | |
CASH FLOW SUMMARY | ||||||||||||||
-2M | 2M | -1.2M | 1.2M | -1.2M | 511K | 262K | -1.2M | 2M | -1.2M | -598K | -124K | 0.0 | 0.0 | |
97.7M | 99.8M | -24.4M | 25.5M | -19.9M | 34.8M | -16.2M | -19M | 20.1M | 9.2M | 19.2M | 2M | 1.5M | 3.6M | |
131.6M | 31.8M | 56.2M | 30.7M | 50.6M | 15.8M | 32M | 51.1M | 31M | 21.8M | 2.5M | 481K | 8.2M | 4.6M | |
229.3M | 131.6M | 31.8M | 56.2M | 30.7M | 50.6M | 15.8M | 32M | 51.1M | 31M | 21.8M | 2.5M | 9.8M | 8.2M | |
-83.3M | -153.3M | -89.7M | -76.5M | -79.1M | -30.3M | -45M | -37.4M | 9.1M | -23.8M | -13.2M | -6.5M | -4.9M | -1.9M |
SEC Filings
KALV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 06, 2025 | October 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 02, 2025 | October 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 29, 2025 | September 24, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | September 11, 2025 | July 31, 2025 | 2025 |
Related Guides
Continue your KALV research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.